Cancer care is 1 of the most complex and costly arenas in healthcare. Fragmented incentives. Siloed data. Patients juggling appointments like it is a 2nd job they never applied for. That is the chaos Atlas Oncology Partners walked into, not with a whiteboard fantasy, but with a balance sheet and a backbone.
Now Atlas Oncology Partners secures $28M in Series A funding. Flare Capital Partners leads the round, with Rubicon Founders doubling down on the company it founded. That is not polite applause. That is conviction capital. When Flare Capital Partners and Rubicon Founders lean in, they are not chasing headlines. They are underwriting a model. And the model is where this gets interesting.
Atlas Oncology Partners embeds interdisciplinary care teams directly into oncology practices. Providers. Nurses. Patient navigators. Social workers. Not circling the building. Inside it. Fully embedded in clinical and virtual workflows, investing in staff and technology so practices can thrive without blowing up existing network contracts or physician relationships. They assume full medical cost risk from payers. Full risk. In oncology. That is not dabbling. That is Atlas carrying weight.
Kate Roberts, President and Co Founder, and David Johnson, MD, MPH, Chief Physician Executive and Co Founder, built this with Rubicon Founders to rethink how cancer care is delivered. Gabrielle Rocque, MD, MSPH, Chief Medical Officer (CMO), alongside Operating Partners Regan Murphy and Deepak Kothavade, round out a leadership team that understands this is not just about margins. It is about multi year, whole panel management across cancer types, from active treatment to surveillance to end of life. That is longitudinal commitment in a system addicted to episodic billing.
The $28M fuels geographic expansion with more oncology practice partners and deeper investment in clinical and operational infrastructure. Translation for operators paying attention: scale the footprint, fortify the engine. You do not assume full medical cost risk unless you trust your data, your workflows, and your people. This is value based care without the buzzword bingo. Access. Quality. Alignment. Say it slowly and it still holds up.
There is a quiet power in working with oncologists, not around them. Atlas Oncology Partners builds on the existing relationship between patient and physician, then layers navigation, psychosocial support, proactive coordination, and expanded in person and virtual access. That is how you drive engagement that actually engages and outcomes that are measurable, not mythical.
For payers staring down oncology spend and for practices feeling the squeeze, this is a signal. When capital flows toward full risk, embedded models in 1 of healthcare’s toughest categories, the market is telling you something. Maybe the future of cancer care is not louder tech. Maybe it is tighter alignment. Atlas Oncology Partners just raised $28M to prove that carrying the risk might be the surest way to carry the patient further.
